treat recurrent UTI with less anti-biotics

empower your patients with innate immune activation

ImmunoRing uses safe extremely low frequency electromagnetic fields to activate innate immune responses at the first sign of UTI symptoms. It is clinically designed to accelerate natural defense mechanisms—reducing reliance on antibiotics and improving patient outcomes.

Controlled electromagnetic field (EMF) exposure modulates immune cell activity. By targeting early-stage immune signaling, the device gives the immune response with a a 3-day head start against urinary tract infections—without pharmacological intervention.

a scientifically proven instant protection Shield

In bacterial and viral infections there is a substantial lag period between infection and immune-system activation. In fact, many bacterial infections play an active role in keeping the immune system asleep while proliferating explosively.

Low-frequency electromagnetic fields (LF-EMF) have been shown to play a significant role in modulating immune responses, particularly through the activation of neutrophils. Studies demonstrate that LF-EMF exposure can counteract immune delays caused by neutrophil dysregulation, reducing the spread of pathogens.

Evidence for this benefit has been published in human and animal, in vivo and ex-vivo studies, where LF-EMF signals activate human neutrophils and reduce tissue damage and mortality through enhanced antimicrobial function. 

The potential of LF-EMF to mitigate recurrent infections such as urinary tract infections (UTIs), by activating neutrophils, presents a groundbreaking approach to infection mitigation. ImmunoRing has transformed these scientific insights into a single, practical device for your patients.

Our journey and where we are today

ImmunoRing R&D undergoes rigorous validation to ensure it meets the highest standards in effectiveness and safety. Our team has a multitude of publications on its name, validating our technology during more over a decade. But let’s be honest: we still have some obstacles to overcome. We are currently in the proces of getting METC approval for our second human clinical study for mitigating rUTI. Afterwards, we still need to go through CE compliance. The aimed result: a device that delivers proven technical capability and clinical reliability.

immunoring clinical study Q4 2026 brainport region

The promise of our R&D is for all early or chronic bacterial and viral infections. Yet, we have decided to focus on Urinary Tract Infections first. rUTI isn’t "just a bladder infection”. It’s a chronic condition for many women with depression rates rivaling other chronic diseases (e.g., diabetes), severe anxiety, and life-altering Quality of Life decline.

We are preparing a clinical study now and ready to empower the medical world with a drug free alternative in treating infections. We’re on a mission to change lives, treating infections with the body’s own immune system instead of anti biotics. Are you a general practitioner, urologist, private clinic owner or investor that believes in doing things differently? Register for our Clinical Study or contact us directly.